Verax Biomedical
US-based Verax Biomedical develops tests for detecting bacterial contaminants in blood products.
Founded
1999US-based Verax Biomedical develops tests for detecting bacterial contaminants in blood products.
Founded in Marlborough, United States, Verax Biomedical is dedicated to developing advanced medical products aimed at detecting bacterial contaminants in blood components. The company's core mission is to enhance the safety of blood transfusions and related therapies through innovative testing solutions. Verax Biomedical's product line includes the Platelet PGD Test, Red Cell PGD Test, and Cell Therapy PGD Test, all designed to identify bacterial contamination, thereby improving patient outcomes and safety in the healthcare sector.
Verax Biomedical has garnered attention for its impactful contributions to medical safety, with its products being utilized across various healthcare facilities in the United States. The company has received significant support from investors focused on healthcare innovation. Notable achievements include FDA approvals for their testing products, which have set new standards in blood safety protocols. Verax Biomedical's technology has significantly reduced the risk of bacterial infections from blood transfusions, marking a substantial impact on public health.
Companies similar to Verax Biomedical include Halcyon Biomedical, Verax Research Services, Velico Medical and Exogenesis.
Verax Biomedical was founded in 1999.
Verax Biomedical's headquarters is located in Marlborough, MA, US.
Verax Biomedical's most recent funding round was for $12.6M (USD) in June 2016.
As of Jun 27, 2016, Verax Biomedical has disclosed funding of $64.8M (USD). Undisclosed round amounts are excluded.
Verax Biomedical has 41 employees as of Feb 5, 2024.
Exogenesis
